Consistently, peripheral administration of orexin A in mice undergoing experimental autoimmune encephalomyelitis (EAE), a well-established model of MS, was shown to induce anti-inflammatory and neuroprotective effects, suggesting that it might constitute a potential therapeutic approach in MS (Becquet et al., 2019). This evidence concerns the gene HCRT and myeloid sarcoma.